AdAlta Pty Ltd. Receives Australian Government Grant To Advance Understanding Of Potential New Lung Fibrosis Therapy
Melbourne, Australia, 31 August, 2016: Biotechnology company AdAlta Limited (ASX: 1AD), specialising in the discovery and development of protein-based therapeutics has received a AU$50,000 Innovation Connections Grant From the Australian Federal Government to support research with The Alfred Hospital and La Trobe University in Melbourne.
The research collaboration will evaluate AdAlta’s lead drug candidate, AD-114, with lung tissue from patients with idiopathic pulmonary fibrosis (IPF). The researchers will seek to provide further validation of the potential of AD-114 as a treatment for idiopathic pulmonary fibrosis as well as exploring its potential as a treatment for other lung fibrosis conditions.
Pre-clinical studies with AD-114 have demonstrated positive in vitro (in the lab) and in vivo (in animals) data in the treatment of idiopathic pulmonary fibrosis. AdAlta has completed an initial analysis of the drug candidate in human lung tissue, and the collaboration with look at a broader number of tissue and blood samples.
AdAlta Limited CEO Sam Cobb said, “This collaboration is important as we move towards first human clinical studies with our lead i-body drug candidate for the treatment of idiopathic pulmonary fibrosis.”
Respiratory Physician at The Alfred Hospital, Dr Glen Westall, said, “We are excited about working with AdAlta to further understand more about this complex disease and how the i-body may play a role for the treatment of a disease for which there is currently no cure.”
AdAlta Chief Scientific Officer, Associate Professor Mick Foley said, “This new research will allow us to further validate the i-body as a potential therapeutic for the treatment of fibrosis and idiopathic pulmonary fibrosis.”
Pre-clinical studies with AD-114 have demonstrated positive in vitro (in the lab) and in vivo (in animals) data in the treatment of idiopathic pulmonary fibrosis. AdAlta has completed an initial analysis of the drug candidate in human lung tissue, and the collaboration with look at a broader number of tissue and blood samples.
AdAlta Limited CEO Sam Cobb said, “This collaboration is important as we move towards first human clinical studies with our lead i-body drug candidate for the treatment of idiopathic pulmonary fibrosis.”
Respiratory Physician at The Alfred Hospital, Dr Glen Westall, said, “We are excited about working with AdAlta to further understand more about this complex disease and how the i-body may play a role for the treatment of a disease for which there is currently no cure.”
AdAlta Chief Scientific Officer, Associate Professor Mick Foley said, “This new research will allow us to further validate the i-body as a potential therapeutic for the treatment of fibrosis and idiopathic pulmonary fibrosis.”